COVID-19 resources / Clinical Research Insights and News

The Cohortias Blog

Stay informed

COVID-19 resources

Cohortias is bringing clinical research to Latin America, now proud to participate in COVID-19 clinical trials.

Our archive includes insights from our experts as they discuss lessons learned over the past three months in managing COVID-19’s impact on trials in Latin America and around the world.

Our blog posts provide insights into what companies should be doing now to prepare for the upcoming ‘new normal’.

Phase III Clinical Trial of BTK inhibitor in Argentina.

Argentina – Phase III Clinical Trial of BTK inhibitor.

Investigational evobrutinib is the first Bruton’s tyrosine kinase (BTK) inhibitor to complete Phase III clinical trial enrolment in relapsing multiple sclerosis.

Trial of KRAS G12C Inhibitor

First-in-human – Phase I/II Trial of KRAS G12C Inhibitor.

Led by Professor Yilong Wu of Guangdong Provincial People’s Hospital, it is an open label, multicenter study treating advanced solid tumors patients with KRAS G12C mutation.

covid-treatment

Clinical Trial Brazil – Proxalutamide as Treatment for COVID-19 Patients.

It is the third ANVISA-approved pivotal study sponsored by Kintor Pharma for the treatment of COVID-19 patients with proxalutamide.

trial-Advanced-solid-tumors

First-in-Human – Phase 1 trial for Advanced Solid Tumors.

First patient has been dosed in the Phase 1 clinical trial evaluating ADCT-901,

COVID-19 Research - Free Consultation

The clinical development journey is fraught with pitfalls and roadblocks; COVID-19 has almost overnight added to the complexity. Innovations, technologies and reinvented processes can help. Our experienced team of experts shares experiences, lessons learned and tips to help you mitigate risk in the current environment while implementing some of the industry’s latest innovations.

covid clinical trials

The presence of clinical research in Latin America has been growing steadily for the last decade, mainly because of cost effectiveness, excellent patient recruitment and the emergence of FDA approved regulatory agencies.